Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2007 1
2008 3
2009 3
2010 5
2011 6
2012 7
2013 11
2014 14
2015 10
2016 11
2017 11
2018 12
2019 19
2020 10
2021 12
2022 8
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab in multiple myeloma.
Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Nooka AK, et al. Among authors: hofmeister cc. Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Cancer. 2019. PMID: 30951198 Free article. Review.
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill JC, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC; Multiple Myeloma Research Consortium; Bergsagel PL, Auclair D, Cho HJ, Robinson DR, Chinnaiyan AM. Vo JN, et al. Nat Commun. 2022 Jun 29;13(1):3750. doi: 10.1038/s41467-022-31430-0. Nat Commun. 2022. PMID: 35768438 Free PMC article.
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.
Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Slade M, et al. Among authors: hofmeister cc. Leukemia. 2022 Dec;36(12):2917-2921. doi: 10.1038/s41375-022-01691-1. Epub 2022 Sep 16. Leukemia. 2022. PMID: 36114265 Free PMC article. Clinical Trial. No abstract available.
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, Oberlton B, Joseph NS, Hofmeister CC, Heffner LT, Dhodapkar MV, Nooka AK, Lonial S, Mitsiades CS, Kaufman JL, Boise LH. Gupta VA, et al. Among authors: hofmeister cc. Blood. 2021 Jul 1;137(26):3604-3615. doi: 10.1182/blood.2020007899. Blood. 2021. PMID: 33649772 Free PMC article.
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, Gupta VA, Boise LH, Lonial S, Nooka AK. Joseph NS, et al. Among authors: hofmeister cc. J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16. J Clin Oncol. 2020. PMID: 32298201 Free PMC article.
The potential of miRNAs as biomarkers for multiple myeloma.
Rocci A, Hofmeister CC, Pichiorri F. Rocci A, et al. Among authors: hofmeister cc. Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Epub 2014 Aug 7. Expert Rev Mol Diagn. 2014. PMID: 25098410 Review.
Most multiple myeloma patients have low testosterone.
John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC. John S, et al. Among authors: hofmeister cc. Leuk Lymphoma. 2019 Mar;60(3):836-838. doi: 10.1080/10428194.2018.1508664. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277092 Free PMC article. No abstract available.
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. Kumar SK, et al. Among authors: hofmeister c. J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002. J Natl Compr Canc Netw. 2018. PMID: 29295877
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Gupta VA, Matulis SM, Barwick BG, Bog RD, Shebelut CW, Shanmugam M, Neri P, Bahlis NJ, Dhodapkar MV, Heffner LT, Hofmeister CC, Joseph NS, Lonial S, Kaufman JL, Jaye DL, Nooka AK, Boise LH. Gupta VA, et al. Among authors: hofmeister cc. Blood Cancer J. 2022 Aug 4;12(8):115. doi: 10.1038/s41408-022-00710-9. Blood Cancer J. 2022. PMID: 35927247 Free PMC article. No abstract available.
129 results